Bio-Matrix Scientific Enters into Validation and Protocol Process.

SAN DIEGO -- Bio-Matrix Scientific Group Inc. (OTCBB: BMSN), a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced today that it has entered into the facility validation process. This process focuses on the validation of systems and equipment involved in the manufacturing of both medical devices and cellular products.

Led by the Company's Chief Scientific Advisor, Dr. Geoffrey O'Neill, Bio-Matrix will develop its facility validation protocols. These protocols form an integral part of Bio-Matrix's Quality System that will comprise its overall Good Manufacturing and Good Tissue Practices (cGMP/cGTP).

Dr. O'Neill noted, "The management of Bio-Matrix has already developed the essential elements of its Quality System, including areas such as its quality policy, management responsibility and quality assessments. The validation process will specifically address procedures to ensure that all equipment and processes provide a quality product and that personnel are trained accordingly. Standard procedures will be developed for medical device production as well as for cellular processing and storage."

Chairman David Koos stated, "The installation, operational and performance qualification (IQ/OQ) of equipment, systems, facilities, and processes for cryogenics, processing, labs and medical devices are an essential part of the validation process. Equipment must be installed, operated, and maintained within design specifications, while processes must be shown to be reliable, all of which to assure the consistent quality and integrity of the product."

According to COO Brian Pockett, "Key staff must provide a basic and thorough understanding in preparing, executing and reviewing protocols. Management has the responsibility for approving and implements these protocols within the framework of its overall quality system."

Once protocols are completed, all Quality Systems documentation will be warehoused in the Company's Regulatory Affairs Department within the facility.

Bio-Matrix's new 15,000 sq ft state-of-the-art facility is located in the heart of the San Diego biotechnology corridor and will house Bio-Matrix's secure Cryogenic Stem Cell Bank, 3 Research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories.

This press release is available on the company's official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to [e-mail] where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.

About Bio-Matrix Scientific Group Inc.

Bio-Matrix Scientific Group Inc. (www.BMSNonline.com), is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in the Biotechnology Corridor of San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.